News and Trends 15 Oct 2020
Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease
Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have been approved in less than a year. Neuromyelitis optica spectrum disorders, previously also known as Devic disease, affect up to 2 in 100,000 people around the world. […]